indomethacin has been researched along with Chronic Pancreatitis in 2 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pilot two-center randomized controlled trial seeks to examine 32 subjects with chronic pancreatitis who have no contraindications to indomethacin." | 9.69 | The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial. ( Cervantes, A; Conwell, DL; Cruz-Monserrate, Z; Han, S; Hao, W; Hart, PA; Lesinski, GB; Li, L; Mace, T; Palermo, TM; Saloman, JL; Topazian, M; Vege, SS; Yadav, D, 2023) |
| " One thousand three hundred and seventy patients with chronic pancreatitis and pancreatic stones (>5 mm in diameter) treated with P-ESWL at Changhai Hospital will be randomly allocated to rectally administered indomethacin or placebo therapy before the procedure." | 9.24 | Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial. ( Chen, H; Du, YQ; Hu, LH; Jiang, X; Jin, ZD; Li, B; Li, ZS; Liao, Z; Liu, F; Qi, YF; Qian, W; Qian, YY; Tang, XY; Wang, D; Wang, LW; Xin, L; Zou, DW; Zou, WB, 2017) |
| "This pilot two-center randomized controlled trial seeks to examine 32 subjects with chronic pancreatitis who have no contraindications to indomethacin." | 5.69 | The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial. ( Cervantes, A; Conwell, DL; Cruz-Monserrate, Z; Han, S; Hao, W; Hart, PA; Lesinski, GB; Li, L; Mace, T; Palermo, TM; Saloman, JL; Topazian, M; Vege, SS; Yadav, D, 2023) |
| " One thousand three hundred and seventy patients with chronic pancreatitis and pancreatic stones (>5 mm in diameter) treated with P-ESWL at Changhai Hospital will be randomly allocated to rectally administered indomethacin or placebo therapy before the procedure." | 5.24 | Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial. ( Chen, H; Du, YQ; Hu, LH; Jiang, X; Jin, ZD; Li, B; Li, ZS; Liao, Z; Liu, F; Qi, YF; Qian, W; Qian, YY; Tang, XY; Wang, D; Wang, LW; Xin, L; Zou, DW; Zou, WB, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, S | 1 |
| Conwell, DL | 1 |
| Li, L | 1 |
| Cervantes, A | 1 |
| Hart, PA | 1 |
| Cruz-Monserrate, Z | 1 |
| Hao, W | 1 |
| Lesinski, GB | 1 |
| Mace, T | 1 |
| Palermo, TM | 1 |
| Saloman, JL | 1 |
| Yadav, D | 1 |
| Vege, SS | 1 |
| Topazian, M | 1 |
| Qian, YY | 1 |
| Chen, H | 1 |
| Tang, XY | 1 |
| Jiang, X | 1 |
| Qian, W | 1 |
| Zou, WB | 1 |
| Xin, L | 1 |
| Li, B | 1 |
| Qi, YF | 1 |
| Hu, LH | 1 |
| Zou, DW | 1 |
| Jin, ZD | 1 |
| Wang, D | 1 |
| Du, YQ | 1 |
| Wang, LW | 1 |
| Liu, F | 1 |
| Li, ZS | 1 |
| Liao, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)[NCT02797067] | Phase 4 | 1,370 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients were identified as post-ESWL pancreatitis if meeting two out of three criteria: pain consistent with acute pancreatitis; amylase or lipase>3 times normal limit; characteristic findings on imaging, in according to the Revised Atlanta International consensus. (NCT02797067)
Timeframe: up to 1 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Indomethacin | 60 |
| Glycerin | 84 |
"Asymptomatic hyperamylasemia was defined as an increase in serum amylase compared with pre-ESWL levels and beyond the upper limit of the normal range but showing no related symptoms. Serum amylase will be measured in all study patients at 3 and 24 hours after the procedure and subsequently at clinical discretion.~Other post-ESWL complications including bleeding, infection, steinstrasse and perforation.~Bleeding is related to clinical evidence，the level of hemoglobin ( measured at 24 hours after the procedure and at clinical discretion) and treatments.~Infection is related to temperature and treatment. Steinstrasse is related to abdominal pain degree and the combination of other complications.~Perforation is related to treatment." (NCT02797067)
Timeframe: up to 1 months
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Infection | Steinstrasse | Perforation | Asymptomatic Hyperamylasemia | Hematuria | Hematemesis | Melena | |
| Glycerin | 13 | 1 | 1 | 197 | 25 | 14 | 16 |
| Indomethacin | 5 | 0 | 0 | 189 | 18 | 9 | 19 |
Post-ESWL complications are also stratified as mild, moderate and severe depending mainly on the length of hospitalization and the need for invasive treatment. (NCT02797067)
Timeframe: up to 1 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Mild | Moderate | Severe | |
| Glycerin | 79 | 5 | 0 |
| Indomethacin | 59 | 1 | 0 |
2 trials available for indomethacin and Chronic Pancreatitis
| Article | Year |
|---|---|
The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase I | 2023 |
Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Calculi; China; Clinical Protocols; | 2017 |